Health 27 February 2026 - 30 March 2026

British American Tobacco Deepens Charlotte’s Web Bet in $75 Million CBD Deal
···

British American Tobacco Deepens Charlotte’s Web Bet in $75 Million CBD Deal

British American Tobacco plans to raise its stake in Charlotte’s Web to about 40% by converting a C$75.3 million debenture and adding $10 million in cash, according to U.S. filings. The deal would erase $65 million of Charlotte’s Web debt and give BAT two board seats if approved by shareholders and the Toronto Stock Exchange. Charlotte’s Web posted a $29.8 million net loss before tax in 2025.
March 31, 2026
GSK plc wins China approval for Exdensur as hepatitis B drug bepirovirsen enters review
····

GSK plc wins China approval for Exdensur as hepatitis B drug bepirovirsen enters review

China approved GSK’s asthma drug Exdensur for patients 12 and older and accepted its hepatitis B candidate bepirovirsen for regulatory review, the company said Monday. Exdensur’s approval followed trials showing it reduced annual asthma attacks by up to 58% versus placebo. The drug will compete with Dupixent and Xolair. Bepirovirsen targets chronic hepatitis B, where current treatments rarely clear the virus.
March 30, 2026
GSK Stock Price Today: Shares Rise After FDA Approval of Lynavoy for Rare Liver-Disease Itch
···

GSK Stock Price Today: Shares Rise After FDA Approval of Lynavoy for Rare Liver-Disease Itch

GSK shares rose 0.6% after the FDA approved Lynavoy, the first U.S. drug specifically for severe itching in primary biliary cholangitis. Alfasigma agreed to pay GSK $300 million upfront for global rights to the drug, plus $100 million more on U.S. approval. GSK and Alfasigma have not disclosed launch pricing or availability. Lynavoy approval follows recent regulatory wins for GSK.
March 19, 2026
GSK Stock Price Today: Shares Drop 2% as Vaccine Policy Risks Keep Investors Cautious
···

GSK Stock Price Today: Shares Drop 2% as Vaccine Policy Risks Keep Investors Cautious

GSK shares fell about 2% in London to 1,973 pence, underperforming the market as European healthcare stocks dropped after an attack on Iran’s Pars gas field. The stock is now 14% below its February 52-week high. GSK repurchased over 11 million shares since Feb. 17. The FDA last week expanded Arexvy RSV vaccine approval to higher-risk adults aged 18 to 49, but CDC guidance is still pending.
March 18, 2026
Haleon PLC’s Centrum Silver May Slow Biological Aging, Nature Medicine Study Finds
···

Haleon PLC’s Centrum Silver May Slow Biological Aging, Nature Medicine Study Finds

A Nature Medicine study found Haleon’s Centrum Silver slowed biological aging markers by about four months over two years in older adults, based on analysis of 958 participants. The effect was statistically significant but small, with authors urging more research. Haleon, facing weak U.S. demand and heavy competition, welcomed the findings but did not influence the trial. The company reported U.S. multivitamin sales rebounded in late 2025.
March 9, 2026
Banco Bradesco Moves Bradsaúde Plan Ahead as Odontoprev Sets April Vote
···

Banco Bradesco Moves Bradsaúde Plan Ahead as Odontoprev Sets April Vote

Bradesco shareholders will vote March 31 on spinning off Bradseg, while Odontoprev holders meet April 6 to approve absorbing Bradesco Gestão de Saúde and renaming as Bradsaúde. The bank says updated documents and a new appraisal do not change the deal’s terms. The reorganization still needs regulator approval and a secondary share sale to meet free float rules has not been scheduled. Bradesco reported 24.7 billion reais profit in 2025.
March 9, 2026
Xenon’s epilepsy drug posts strong Phase 3 data; XENE shares jump ahead of U.S. filing
···

Xenon’s epilepsy drug posts strong Phase 3 data; XENE shares jump ahead of U.S. filing

Xenon Pharmaceuticals said its Phase 3 trial showed azetukalner cut monthly focal onset seizures by 53.2% at the 25 mg dose versus 10.4% for placebo. Shares rose over 40% in premarket trading. The company plans to file for U.S. FDA approval in the third quarter of 2026. Dizziness was the most common side effect, with higher discontinuations in the 25 mg group.
March 9, 2026
Moderna’s $2.25 billion patent settlement clears a major cloud over its COVID vaccine tech
···

Moderna’s $2.25 billion patent settlement clears a major cloud over its COVID vaccine tech

Moderna will pay $950 million to Arbutus Biopharma and Genevant Sciences in the third quarter of 2026 to settle mRNA vaccine patent litigation, with no future royalties owed. The deal, reached before a Delaware jury trial, includes a court judgment of infringement and a non-exclusive license for lipid nanoparticle technology. Moderna’s stock jumped after the news. An additional $1.3 billion could be owed, depending on an ongoing appeal.
March 5, 2026
Moderna’s $2.25 billion patent settlement: the deal that ends a COVID vaccine fight and reshapes its pipeline
···

Moderna’s $2.25 billion patent settlement: the deal that ends a COVID vaccine fight and reshapes its pipeline

Moderna will pay up to $2.25 billion to settle a patent dispute with Genevant Sciences and Arbutus Biopharma over lipid nanoparticle technology in its COVID-19 vaccine, avoiding a Delaware trial. The settlement includes a $950 million upfront payment and up to $1.3 billion more tied to an appeal. Moderna shares rose over 10% after the news. The deal grants Moderna a global license for certain infectious-disease vaccines.
March 4, 2026
Amgen stock slides as Kyowa Kirin halts rocatinlimab trials on cancer concerns
···

Amgen stock slides as Kyowa Kirin halts rocatinlimab trials on cancer concerns

Amgen shares dropped 2.3% to $377.01 after Kyowa Kirin halted all trials of the experimental drug rocatinlimab due to new safety concerns, including cases of malignancy. Kyowa Kirin had already ended its development partnership with Amgen. The decline outpaced broader healthcare and biotech sector losses. Investors await further safety disclosures and Amgen’s next quarterly results in late April.
March 3, 2026
Johnson & Johnson stock drifts lower as FDA flags fresh Impella heart-pump recalls
···

Johnson & Johnson stock drifts lower as FDA flags fresh Impella heart-pump recalls

Johnson & Johnson shares fell 0.2% to $247.98 Monday after the FDA finalized three Class I recalls for certain Impella RP heart pumps linked to 22 injuries. The recalls cite sensor drift causing inaccurate readings but no deaths. Separately, a court in New Jersey will address J&J’s effort to disqualify a plaintiffs’ firm from ongoing talc litigation on Tuesday.
March 2, 2026
Eli Lilly stock rises as new orforglipron data puts side effects in the spotlight
···

Eli Lilly stock rises as new orforglipron data puts side effects in the spotlight

Eli Lilly shares rose 0.8% Friday after full trial results for its oral diabetes drug orforglipron showed higher discontinuation rates—8.7% to 9.7%—than Novo Nordisk’s oral semaglutide, which saw 4.5% to 4.9%. The study found orforglipron led to greater blood sugar and weight loss, but more side effects. Investors are watching for U.S. regulatory decisions on obesity use, expected in the second quarter.
February 27, 2026
1 2 3 4